Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations

Adlai Nortye appointed Christopher Liu, PharmD, as Head of Investor Relations and Public Relations. Dr. Liu brings nearly a decade of biotech equity research experience, most recently as a Managing Director at Lucid Capital Markets covering oncology.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.